The cost of cancer care
Te complexity of health care spending in the United States arises from an economic environment in which patients spend not only their own personal resources, but also the pooled resources of others, in the form of third-party public or private payers. 1 Tis multilayered payment structure protects individual consumers from the sometimes exorbitant costs of health care goods and services, but can also make it difcult for them to judge the relative economic value of various medical interventions.
Unfortunately, a system with extensive cost sharing may inherently incentivize the inefcient use of limited health care resources. At the same time, one would expect demand for interventions of only modest beneft to decline rapidly if out-of-pocket expenses were to increase. 1 Te history of cost sharing can be traced back to the landmark RAND Health Insurance Experiment (HIE), which suggested that cost sharing could decrease health care expenditures without signifcantly increasing the risk of adverse health outcomes. 5 Subsequently, these fndings have been cited by insurers to justify additional cost sharing between themselves and the patients they insure. 4 In contrast to the fndings of the RAND study, there is substantial evidence that cost sharing may increase the risk of adverse outcomes, especially for selected groups of patients. One study estimated that for every 1% increase in insurance premiums, between 164,000 and 300,000 patients would be expected to lose their employer-sponsored insurance coverage. 6 From an oncologic perspective, it has been presumed that such patients would be more likely to The cost of cancer care is increasing, with important implicatons for the delivery of high-quality, patent-centered care. In the clinical setng, patents and physicians express a desire to discuss out-of-pocket costs. Nevertheless, both groups feel inadequately prepared to partcipate in these discussions, and perhaps not surprisingly, the integraton of these discussions into clinical practce seems to be the excepton rather than the rule. The resultng neglect of fnancial issues has the potental to cause unnecessary sufering for oncology patents. In this paper, we review the most relevant literature on fnancial toxicity in cancer care. In additon, we discuss potental predictors of fnancial toxicity, and the recent development of instruments to help clinicians and researchers quantfy fnancial burden.
Review experience poor clinical outcomes, with lower rates of cancer screening, later stage at cancer diagnosis, and higher cancer-specifc mortality. 7 Even patients with insurance can sufer from signifcant fnancial burden, potentially leading to delayed initiation of treatment, medication noncompliance, and personal bankruptcy. 8, 9 A national survey of patients declaring bankruptcy for medical reasons found that more than 75% of them reported being insured at the onset of their illness. 10 Among this group of patients, cancer was the most costly diagnosis, with mean out-of-pocket expenditures exceeding $35,000. 10 Te prevalence of fnancial burden among cancer patients seems to be signifcant. Studies of cancer patients, specifcally, have found varying levels of self-reported fnancial distress, ranging from 32%-85%. 4, 11 In a longitudinal survey of patients with nonmetastatic breast cancer, a third of patients reported a decline in fnancial status in the period following diagnosis, with a signifcant minority reporting out-of-pocket costs that exceeded $5,000 per year. 12 A national survey of nonelderly adults found higher out-ofpocket burden (broadly defned as health-related spending greater than 20% of annual income) among cancer patients, compared with others with or without chronic medical conditions. 13 In this context, the efcacy of patient-physician communication regarding fnancial issues has become increasingly important, with both the American Society of Clinical Oncology and the Institute of Medicine categorizing cost of care discussions as an essential component of high-quality care. 8, 14 Medication nonadherence Te medical consequences of fnancially toxic cancer care can be signifcant. In particular, there is ample data correlating higher out-of-pocket costs with medication nonadherence in cancer patients. In a single-center survey of 300 cancer patients, 16% of patients reported high or overwhelming fnancial distress, and 27% reported medication nonadherence because of fnancial concerns. 15 Fiftytwo percent of those patients reported a desire to discuss out-of-pocket costs with their physician, whereas just 19% reported having had these discussions. 15 Patients who experienced higher-than-expected fnancial burden were especially likely to be nonadherent. 15 Tese fndings suggest that setting realistic fnancial expectations could decrease the risk of nonadherence. Medication nonadherence provides immediate cost-savings for the patient, but increases the risk of various adverse outcomes. In fact, an estimated 33%-69% of all hospital admissions have been attributed to nonadherence, with an annual price tag of up to $100 billion. 16 Additional data supporting the link between out-ofpocket fnancial burden and medication nonadherence comes from a retrospective cohort study of aromatase inhibitors in patients with breast cancer. 17 In this study, copayments of more than $30 a month were independently associated with nonpersistence, defned as a gap in prescription use of more than 45 days, among women older than 65 years. 17 Findings from multiple studies have demonstrated an association between early discontinuation of aromatase inhibitors and worse overall survival in breast cancer patients. 17 Similarly, chronic myeloid leukemia patients with higher copayments were almost twice as likely as those with lower copayments to discontinue treatment with tyrosine kinase inhibitors during the frst 180 days of treatment (17% vs 10%, respectively). 18 Of course, fnancial concerns may not be the primary driver of medication nonadherence in these patients, and these studies may or may not have sufciently controlled for other relevant variables.
In a more selected cohort of cancer patients applying for copayment assistance, 42% reported signifcant or catastrophic fnancial burden, and 20% of those patients reported taking less than the prescribed amount of medication for fnancial reasons. 4 In this cohort, self-reported fnancial burden was similarly associated with several other coping behaviors, including reduced spending on leisure activities, selling possessions or property, and use of savings to pay for treatment-related expenses. 4 Physicians have begun to recognize that out-of-pocket costs can contribute to unacceptable levels of fnancial distress among cancer patients. 19 Unfortunately, discussing the fnancial implications of various treatment regimens can be exceedingly difcult. Inconsistent defnitions of out-of-pocket costs, and difculty predicting their magnitude, are 2 of the most frequently cited factors preventing efective cost of care communication. Some researchers use to the term "out-of-pocket" specifcally to refer to the unreimbursed costs of treatment among insured individuals, whereas others include any therapy intended to prevent complications of treatment (such as administration of myeloid growth factors, blood transfusions, and antiemetics), along with costs of services meant to improve quality of life (such as acupuncture, home care, and physical therapy). Because costs for some or all of these services are unpredictably afected by treatment choice, insurance requirements, and pharmaceutical pricing, it may be impossible for physicians to accurately predict the costs of care for an individual patient. 19 Understanding the diference between the total costs of the treatment and the total charges paid by the individual may be beyond the reasonable scope of practice for many providers. Similarly, it may be impossible for providers to accurately predict the cost-efectiveness of a treatment for any particular patient, because the benefts of treatment can be expected to vary widely among diferent individuals. In some cases, it may be preferable for providers to recommend more costly treatments when given several options with similar clinical efcacy, because of patient-specifc concerns regarding side efects, convenience, or quality of life.
Despite these challenges, multiple authors have hypothesized that efective out-of-pocket cost discussions might facilitate the delivery of higher-quality patient care. 19 Cost discussions could help patients choose lower-cost treatment regimens, especially when faced with therapeutically equivalent alternatives. 19 Furthermore, these discussions could allow patients to make purposeful concessions of therapeutic beneft to ensure lower personal fnancial burden. 19 Finally, incorporating cost considerations into routine clinical decision-making could encourage more efcient delivery of quality care, which may have particular importance for more severely resource-limited settings.
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Financial distress and quality of life Tere is increasingly strong evidence supporting the relationship between higher levels of fnancial distress and decreased quality of life. Among solid tumor patients undergoing active treatment, up to 47% report signifcant or catastrophic fnancial burden, with high levels of burden associated with low levels of patient satisfaction. 20 Understanding this association may help identify interventions to improve patient satisfaction, which is increasingly being used as a metric for delivery of patient-centered care. 20 It is interesting to note that patient satisfaction with a physician's interpersonal manner, communication skills, and accessibility had no association with fnancial burden, suggesting that patients may continue to view individual physicians favorably despite signifcant fnancial burden. 20 Fenn and colleagues, in a national survey of more than 2,000 cancer survivors, found that 30% of respondents reported some degree of cancer-related fnancial distress (in response to the question, "To what degree has cancer caused fnancial problems for you and your family?"). 21 Most importantly, the authors found that the degree to which cancer caused fnancial problems, when compared with various other factors (including age, race, insurance status, and family income), was the strongest independent predictor of quality of life. 21 In a study of cancer survivors, Zafar and colleagues found that high fnancial burden (defned as difculty living on total household income) was associated with poorer quality of life, as measured by responses to the EuroQol group's self-reported measure, the EQ-5D. 22 In a separate cohort of patients with advanced cancer, DelgadoGuay and colleagues found that fnancial distress was correlated with health-related quality of life (HR-QoL), as measured by the Functional Assessment of Chronic Illness Terapy-General (FACT-G; r = 0.23, P = .0057). 23 Finally, de Souza and colleagues, using a fnancial toxicity patientreported outcome measure (PROM) 24, 25 termed COST (Comprehensive Score for Financial Toxicity), reported a statistically signifcant correlation between the patient's fnancial toxicity score and HR-QoL, as measured by the FACT-G (r = 0.42, P < .001).
26
Willingness to pay Te extent to which individual patients will pay for marginally better clinical outcomes has been examined. Johnson and colleagues conducted a discrete choice experiment to explore willingness to pay for prophylactic granulocyte colony-stimulating factor to decrease the risk of febrile neutropenia. 27 In this study, patients were willing to pay more than $1,000 to reduce the risk of disrupting their chemotherapy schedule, and more than $800 to reduce the risk of infection. 27 Among patients with non-Hodgkin lymphoma, a similar experiment found that for each $10 increase in out-of-pocket costs, the adjusted odds ratio for accepting outpatient care for febrile neutropenia was 0.84. 28 It is interesting to note that the adjusted odds ratio for accepting outpatient care was even lower (0.53) for each 5% increase in probability of return to the hospital, suggesting that risk of hospitalization may be a greater deterrent than small increases in out-of-pocket costs. 28 A study by Wong and colleagues similarly explored the complex decision-making of cancer patients faced with trade-ofs between cost, efcacy, and toxicity. 29 When presented with hypothetical treatment scenarios, patients with higher incomes were more likely to prioritize survival, whereas patients with lower incomes were more likely to prioritize avoidance of expensive treatments, regardless of survival or toxicity. Te authors concluded that insurance plans with greater cost sharing may increase disparities in cancer care, specifcally owing to cost-aversive behaviors among low-income patients. 29 Willingness to pay for better overall survival is more difcult to assess systematically. An Australian study presented patients with a hypothetical scenario, asking whether they would be willing to pay $25,000 out-of-pocket for an additional 4-6 months of survival. Among this patient population, about half of the patients (51%) expressed a willingness to do so. 
Patient-physician communication and cost of care
Numerous potential obstacles can preclude efective costof-care discussions between patients and physicians. For patients, these barriers include uncertainty about the appropriateness of the topic, embarrassment, and the perception that a physician's time is limited. 31 Some patients may hypothesize that voluntarily sharing stories of fnancial distress would compromise quality of care, by encouraging physicians to recommend less expensive, and potentially less efective, treatments. 32, 33 For physicians, potential barriers include a lack of knowledge about a patient's socioeconomic status, and uncertainty about a patient's desire to discuss the costs of care. 31 A survey of medical oncologists found that most (80%) Review thought it was important to be explicit about the potential fnancial impact of treatment choices. 31 However, nearly 1 in 3 oncologists reported a high degree of discomfort about having these discussions with patients. Some oncologists avoid cost considerations entirely, focusing exclusively on treatments with maximal clinical beneft. 31 A survey of breast cancer patients found that 94% of respondents thought physicians should discuss costs of care, whereas 14% reported having actually had such discussions. 34 Another survey of cancer patients found that a majority (59%) wanted physicians to discuss out-of-pocket costs with them. However, a similar percentage (57%) reported that they did not integrate out-of-pocket costs into their individual medical decision-making process. 35 Tese fndings are supported by a smaller study of patients with localized prostate cancer, in which more than 90% of respondents, including patients with high fnancial burden, reported that they would not have chosen a diferent treatment, even if they had prior knowledge of out-of-pocket costs. 36 Consequently, the desire to discuss treatment costs should not be assumed to represent a simultaneous desire to integrate cost-saving behaviors into clinical decision making. 35 In a survey of breast cancer patients, almost all (96%) wanted to discuss expensive drug options, even if they were unlikely to be afordable. 25 Similar data were found in a study among Australian cancer patients, with more than 90% of patients expressing a desire to learn about prohibitively expensive cancer treatments. 30 Te integration of midlevel providers, social workers, and registered nurses into cost-of-care discussions may facilitate more timely and efective communication. Unfortunately, there are very few published studies of cost communication practices among nonphysician providers. A single-center qualitative survey reported frustration among social workers about the lack of fnancial resources for patients, institutional barriers, and limited resources for identifcation of at-risk patients.
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Financial toxicity: an emerging concept Te terms fnancial distress, fnancial burden, and fnancial toxicity have been used interchangeably to describe the fnancial impact of cancer care. 9, 38 Financial toxicity, in particular, was frst referenced in 2009 to underscore the dramatic economic efects of modern oncology drugs, and has since been adopted by multiple authors. 4, 24, 39, 40 Tis term emphasizes the clinical relevance of fnancial distress, as an equivalent to the more widely acknowledged physical and psychological toxicities of cancer treatment.
Identifying patients who are at highest risk of fnancial toxicity has been challenging. In a study of patients with colorectal cancer, the presence of postsurgical complications was associated with higher levels of fnancial burden and higher self-reported fnancial worry. 41 A study from the pediatric oncology literature found that younger, less educated parents were more likely to report fnancial hardship. 42 In another study, a correlation was found between unexpected hospitalizations, employment disruptions, and reported fnancial burden among primary caretakers of children with cancer. 43 Older studies have suggested that fnancial toxicity peaks immediately after the time of diagnosis, when admissions are frequent, work disruptions are ubiquitous, and insurance benefts have yet to be distributed. 44, 45 Among adult patients, both younger age and larger household size have been associated with fnancial toxicit y. 4 Fenn and colleagues found that patients reporting "a lot" of fnancial distress were more likely to be nonwhite, female, and younger than 61 years old, with a total annual household income of less than $35,000, and less than a college degree. 21 Among patients with nonmetastatic breast cancer, underserved patients were most vulnerable to fnancial decline, after adjusting for income, educational level, and employment status. 12 Among patients with stage III colorectal cancer receiving adjuvant chemotherapy, the 2 factors most strongly associated with fnancial hardship were younger age and lower annual household income. 46 In a cohort of patients with solid tumors seeking fnancial assistance, use of cost-coping strategies was associated with younger age, lower income, higher education, and shorter duration of chemotherapy. 47 Younger patients may have more difculty than older individuals in adjusting to the fnancial pressures of cancer care for many reasons, including higher baseline household expenses and less time to accumulate necessary fnancial assets. 46 In a recent study, Huntington and colleagues used the COST instrument to assess 100 insured patients with multiple myeloma. 48 In that population, younger age (P = .0092), lower household income (P = .0031), nonmarried status (P = .0074), and longer time since diagnosis (P = .042) were associated with greater fnancial toxicity.
It is certainly possibly, if not likely, that diferent diseases have diferent drivers of fnancial toxicity. Terefore, the adoption of a validated tool for the measurement of fnancial toxicity, encompassing both out-of-pocket costs and loss-of-income concerns, is necessary to facilitate accurate comparisons of fnancial toxicity among diferent populations. For these reasons, de Souza and colleagues developed the COST Patient-Reported Outcome Measure, using standardized statistical methods, to more accurately quantify fnancial toxicity among diferent cohorts of cancer patients. 24, 28 In the development study performed in 155 patients, the single-factor solution explained 93% of the variance in the data, with communalities between 0.3 and 0.7. Te Cronbach alpha coefcient for the 11-item COST measure was 0.9, indicating excellent internal consistency. Mean inter-item and item-total correlations were 0.47 (range, 0.22-0.69) and 0.71 (range, 0.62-0.79), respectively, demonstrating nonredundancy and good construct validity. 24 In a second cohort of 233 patients with advanced cancers, the authors demonstrated a signifcant relationship between fnancial toxicity and younger age (P < .01), nonwhite ethnicity (P < .05), less than a college degree (P < .01), unemployment (P < .001), Medicaid insurance (P < .05), and lower income (P < .001). 26 In addition, subsequent data from this cohort clearly demonstrated a graded relationship between fnancial toxicity (as measured by the COST instrument) and health-related quality of life. 26 Adapting questions from the National Consumer Bankruptcy Project, Veenstra and colleagues developed a similar patient-reported outcome measure for patients with a current or prior history of stage III colorectal cancer. 49 Te composite measure was internally validated within the same sample against a binary question (My illness has had no impact on my fnances) and a single question about fnancial worry (How much do you worry about fnancial problems that have resulted from your colorectal cancer and its treatment?). Among the 956 colorectal cancer patients, factor analysis of 7 burden items yielded a single-factor solution, with all factor loadings greater than 0.4. Internal consistency as measured by the Cronbach alpha was 0.79. 49 Another commonly used instrument for quantifying fnancial distress is the Financial Well-Being Scale, a 10-item survey to evaluate the general population's reactions to their fnancial situation. 50 Other studies have used single-item questionnaires to associate fnancial problems with various quality of life measures. 22, 23 Te decision regarding which instrument to use should be determined by the emerging body of literature supporting their development and validation, as well as their association with clinically meaningful outcomes. Future integration of these instruments into routine clinical practice may promote earlier identifcation of patients at risk for fnancial toxicity, and ensure more transparent and standardized evaluations of fnancial health.
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Conclusions
Te fnancial burden of cancer care in the United States is a growing problem for all stakeholders, including patients, providers, and third-party payers, with signifcant medical, psychological, and behavioral consequences. Te current medical literature provides consistent evidence that fnancial toxicity can afect clinically relevant outcomes, like medication adherence and quality of life. Multiple authors have expressed the opinion that physicians should take a leading role in promoting cost-efective cancer care, and clearly communicate with patients regarding potential outof-pocket costs. As a consequence of recent national health care reforms in the United States, many experts expect to see a trend toward lower out-of-pocket costs, especially among the previously uninsured. 13 Nevertheless, in an era of ongoing and potentially unsustainable increases in the cost of care, fnancial toxicity should be expected to emerge as an increasingly relevant clinical problem, with far-reaching implications for the delivery of high quality, patientcentered cancer care.
